circPTPN12 promotes the progression and sunitinib resistance of renal cancer via hnRNPM/IL-6/STAT3 pathway

Renal cell carcinoma (RCC) is characterized by the difficulties in early diagnosis and the propensity to metastases. For advanced RCC, sunitinib targeted therapy is the clinically recommended first-line drug and the major challenge of sunitinib treatment is adaptive resistance. Therefore, it is impe...

Descripción completa

Detalles Bibliográficos
Autores principales: Shou, Yi, Yue, Changjie, Wang, Qi, Liu, Jingchong, Xu, Jiaju, Miao, Qi, Liu, Di, Yang, Hongmei, Liu, Yuenan, Zhang, Xiaoping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10066201/
https://www.ncbi.nlm.nih.gov/pubmed/37002206
http://dx.doi.org/10.1038/s41419-023-05717-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10066201/
https://www.ncbi.nlm.nih.gov/pubmed/37002206
http://dx.doi.org/10.1038/s41419-023-05717-z

Ejemplares similares